The efficacy and safety of tocilizumab in patients with neuromyelitis optica
Not Applicable
- Conditions
- neuromyelitis optica
- Registration Number
- JPRN-UMIN000022201
- Lead Sponsor
- Department of Neurology, Shimane University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 3
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with severe infection such at tuberculosis, pneumocystis carinii pneumonia, nontuberculosis mycobacterial infection, hepatitis B,hepatitis C, or chronic active FB virus infection. 2)Patients with a history of hypersensitivity to this drug. 3)Patients with interstitial pneumoniris. 4)Patients with lymphopenia.(lymphocyte number <500/mm3) 5)Pregnant women or patients with possible pregnancy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relapse tate up to years EDSS up to 2 years
- Secondary Outcome Measures
Name Time Method